• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperfine Announces Proposed Public Offering

    10/15/25 4:06:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email

    Hyperfine, Inc. (NASDAQ:HYPR) ("Hyperfine" or the "Company") today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the underwriters a 30-day option to purchase up to 15% of the total number of securities sold in the offering (consisting of shares of Class A common stock, pre-funded warrants or any combination thereof), on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Lake Street Capital Markets is acting as the sole book-runner for the proposed offering.

    The securities are being offered and sold by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275449) previously filed with the U.S. Securities and Exchange Commission (the "SEC") on November 9, 2023 and declared effective by the SEC on November 22, 2023. The offering of such securities is being made only by means of a prospectus supplement that forms a part of the registration statement. A preliminary prospectus supplement and accompanying base prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC's website at http://www.sec.gov. When available, copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the offering may be obtained from Lake Street Capital Markets, LLC at 121 South Eighth Street, Suite 1000, Minneapolis, MN 55402, or e-mail at [email protected]. The final terms of the proposed offering will be disclosed in a final prospectus supplement to be filed with the SEC.

    This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

    About Hyperfine, Inc.

    Hyperfine is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

    Cautionary Note Regarding Forward-Looking Statements

    This press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the uncertainties related to market conditions and the completion of the offering on the anticipated terms, or at all. These statements are based on the Company's current expectations or beliefs and are subject to uncertainty and changes in circumstances. Actual results may vary materially from those expressed or implied by the statements here due to changes in market, economic, business, competitive or regulatory factors, and other risks and uncertainties, including those set forth in the Company's filings with the SEC, including in the preliminary prospectus supplement related to the offering, to be filed with the SEC, the Company's most recent Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 17, 2025, and the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025 and June 30, 2025, filed with the SEC on May 13, 2025 and August 13, 2025, respectively, and in other filings the Company makes with the SEC from time to time. The Company cautions readers that these statements are not exclusive and that readers should not place undue reliance upon any forward-looking statements. The forward-looking statements in this press release speak only as of the date of this press release. The Company does not undertake any obligation to update or revise these forward-looking statements for any reason, except as required by law.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20251015094035/en/

    Media Contact

    Devin Zell

    Hyperfine

    [email protected]

    Investor Contact

    Webb Campbell

    Gilmartin Group LLC

    [email protected]

    Get the next $HYPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperfine Announces Publication of Breakthrough Clinical Data Demonstrating the Swoop® System's Enhanced Stroke Detection Capabilities

    The largest dataset to date on stroke detection with the Swoop® system demonstrates the ability to identify small strokes rapidly and reliably, reinforcing its clinical value for acute care and emergency settings. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the largest data set to date evaluating stroke detection with the Swoop® system. This data provides strong evidence supporting the use of AI-powered portable MRI for stroke detection in multiple clinical settings, including the emergency department. The

    1/27/26 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Announces NEURO PMR Study Results Showing High Diagnostic Value and Superior Patient Experience in Neurology Clinics

    Data presented at the annual American Society of Neuroimaging meeting supports clinical value and broad utility of the portable Swoop® system in outpatient neurology. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced results from the NEURO PMR study, presented by Dr. Laszlo Mechtler at the American Society of Neuroimaging (ASN) Annual Meeting in San Juan, Puerto Rico on January 16, 2026. NEURO PMR (Neurological Evaluation in the Office with Portable MR) is the first prospective, multi-center, real-world study to evaluate the

    1/20/26 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic

    ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 16, 2026 /PRNewswire/ -- The medical imaging world is hitting a massive reset button as AI-driven clinical intelligence transforms how we map the human heart. With the medical image management market projected to hit $9.06 billion by 2032[1], the era of bulky, multi-million dollar hardware is giving way to agile, software-defined diagnostics. As point-of-care tools accelerate toward a $70.92 billion market[2], hospitals are trading dedicated MRI suites for bedside intelligence that delivers hospital-grade precision on a portable device. This seismic shift is placing a massive premium on the

    1/16/26 11:56:00 AM ET
    $BFLY
    $GEHC
    $HOLX
    Medical Electronics
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $HYPR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Hyperfine Inc.

    SCHEDULE 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    1/30/26 2:18:12 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    1/12/26 8:28:11 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 8-K filed by Hyperfine Inc.

    8-K - Hyperfine, Inc. (0001833769) (Filer)

    12/29/25 4:17:46 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hyperfine downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

    8/11/22 6:32:27 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Evercore ISI initiated coverage on Hyperfine with a new price target

    Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

    5/31/22 7:16:51 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Wells Fargo initiated coverage on Hyperfine with a new price target

    Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

    4/14/22 7:32:25 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Teisseyre Thomas sold $1,517 worth of shares (1,405 units at $1.08), decreasing direct ownership by 0.37% to 379,657 units (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    11/19/25 7:07:43 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Chief Operating Officer Teisseyre Thomas sold $1,531 worth of shares (1,151 units at $1.33), decreasing direct ownership by 0.30% to 381,062 units (SEC Form 4)

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    8/18/25 4:10:40 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Wolterman Dan

    4 - Hyperfine, Inc. (0001833769) (Issuer)

    6/6/25 4:01:04 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    View All

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    QuidelOrtho Announces Appointment of Two Independent Directors to its Board

    Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

    12/10/24 7:00:00 AM ET
    $CTLT
    $HYPR
    $NVST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

    Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

    12/3/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Hyperfine Inc.

    SC 13G - Hyperfine, Inc. (0001833769) (Subject)

    2/13/24 5:06:19 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    2/14/23 4:07:09 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

    SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

    12/20/22 4:22:37 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $HYPR
    Financials

    Live finance-specific insights

    View All

    Hyperfine Announces FDA Clearance of the First Optive AI™ Software Update with Advanced Diffusion Imaging Capability, Focused on Enhancing Stroke Detection with the Swoop® System

    A new multi-direction DWI sequence, the latest Swoop® system software, and the first advancement in Hyperfine's Optive AI™ software, delivers clearer, higher-quality images for stroke diagnosis, enhancing the value of the Swoop® system in acute neurological care. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it has received FDA clearance for a new multi-direction diffusion-weighted imaging (DWI) software sequence. This advancement delivers substantially improved image quality and diagnostic confidence for stroke detect

    12/15/25 8:15:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. to Announce Third Quarter 2025 Financial Results on November 13, 2025

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that it will report full financial results for the third quarter 2025 on Thursday, November 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. For more

    10/30/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Hyperfine, Inc. Reports Second Quarter 2025 Financial Results

    GUILFORD, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2025 financial results and provided a business update. "In the second quarter, we executed across our key growth drivers. We received FDA clearances for our latest software, Optive AITM, and for the next generation Swoop® system powered by Optive AITM software, which represent a key inflection point in our technology. We also completed our pilot neurology office program. We believe these criti

    8/13/25 4:05:00 PM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care